Dopaminergic modulation of positive expectations for goal-directed action: evidence from Parkinson’s disease

Parkinson’s disease (PD) impairs the control of movement and cognition, including the planning of action and its consequences. This provides the opportunity to study the dopaminergic influences on the perception and awareness of action. Here we examined the perception of the outcome of a goal-directed action made by medicated patients with PD. A visuomotor task probed the integration of sensorimotor signals with the positive expectations of outcomes (Self priors), which in healthy adults bias perception toward success in proportion to trait optimism. We tested the hypotheses that (i) the priors on the perception of the consequences of one’s own actions differ between patients and age- and sex-matched controls, and (ii) that these priors are modulated by the levodopa dose equivalent (LDEs) in patients. There was no overall difference between patients and controls in the perceptual priors used. However, the precision of patient priors was inversely related to their LDE. Patients with high LDE showed more accurate priors, representing predictions that were closer to the true distribution of performance. Such accuracy has previously been demonstrated when observing the actions of others, suggesting abnormal awareness of action in these patients. These results confirm a link between dopamine and the positive expectation of the outcome of one’s own actions, and may have implications for the management of PD.

[1]  John R Hodges,et al.  The Addenbrooke's Cognitive Examination Revised (ACE‐R): a brief cognitive test battery for dementia screening , 2006, International journal of geriatric psychiatry.

[2]  H. Bergman,et al.  Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease , 2010, Nature Reviews Neuroscience.

[3]  D. Eckstein,et al.  Parkinson's disease and dopaminergic therapy—differential effects on movement, reward and cognition , 2008, Brain : a journal of neurology.

[4]  Catalin V. Buhusi,et al.  What makes us tick? Functional and neural mechanisms of interval timing , 2005, Nature Reviews Neuroscience.

[5]  Roger A. Barker,et al.  Dynamic causal modelling of effective connectivity from fMRI: Are results reproducible and sensitive to Parkinson's disease and its treatment? , 2010, NeuroImage.

[6]  M. D’Esposito,et al.  Inverted-U–Shaped Dopamine Actions on Human Working Memory and Cognitive Control , 2011, Biological Psychiatry.

[7]  F. Horak,et al.  Step initiation in Parkinson's disease: Influence of levodopa and external sensory triggers , 1997, Movement disorders : official journal of the Movement Disorder Society.

[8]  P. O'Suilleabhain,et al.  Proprioception in Parkinson's disease is acutely depressed by dopaminergic medications , 2001, Journal of Neurology Neurosurgery & Psychiatry.

[9]  Karl J. Friston,et al.  Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. , 1999, Brain : a journal of neurology.

[10]  C. Marsden,et al.  'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. , 1988, Brain : a journal of neurology.

[11]  M. Borutta,et al.  A defect of kinesthesia in Parkinson's disease , 1995, Movement disorders : official journal of the Movement Disorder Society.

[12]  E. Phelps,et al.  Neural mechanisms mediating optimism bias , 2007, Nature.

[13]  R. Barker,et al.  Parkinson's disease and healthy aging: Independent and interacting effects on action selection , 2010, Human brain mapping.

[14]  Konrad Paul Kording,et al.  Bayesian integration in sensorimotor learning , 2004, Nature.

[15]  A. Raftery Bayesian Model Selection in Social Research , 1995 .

[16]  M. Jahanshahi,et al.  Time estimation and reproduction is abnormal in Parkinson's disease. , 1992, Brain : a journal of neurology.

[17]  Howard Poizner,et al.  Impaired Endogenously Evoked Automated Reaching in Parkinson's Disease , 2011, The Journal of Neuroscience.

[18]  David J. Brooks,et al.  Genetic impact on cognition and brain function in newly diagnosed Parkinson’s disease: ICICLE-PD study , 2014, Brain : a journal of neurology.

[19]  C D Marsden,et al.  Depression in Parkinson's disease: a quantitative and qualitative analysis. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[20]  Shelley E. Taylor,et al.  Illusion and well-being: a social psychological perspective on mental health. , 1988, Psychological bulletin.

[21]  L. Abramson,et al.  Depressive realism: Four theoretical perspectives. , 1988 .

[22]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[23]  P. Petrovic,et al.  Believing is seeing: expectations alter visual awareness , 2008, Current Biology.

[24]  J. Konczak,et al.  The effect of dopamine replacement therapy on haptic sensitivity in Parkinson’s disease , 2010, Journal of Neurology.

[25]  R. Dolan,et al.  Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans , 2006, Nature.

[26]  P. Cardoso-Leite,et al.  Neuroscience and Biobehavioral Reviews Action effect anticipation: Neurophysiological basis and functional consequences (cid:2) , 2022 .

[27]  H. Shibasaki,et al.  Oculomotor abnormalities in Parkinson's disease. , 1979, Archives of neurology.

[28]  R. Cools Dopaminergic modulation of cognitive function-implications for l-DOPA treatment in Parkinson's disease , 2006, Neuroscience & Biobehavioral Reviews.

[29]  T. Flash,et al.  Kinematic analysis of upper limb trajectories in Parkinson's disease , 1992, Experimental Neurology.

[30]  T. Robbins,et al.  Catechol O-Methyltransferase val158met Genotype Influences Frontoparietal Activity during Planning in Patients with Parkinson's Disease , 2007, The Journal of Neuroscience.

[31]  P. Haggard,et al.  Voluntary action and conscious awareness , 2002, Nature Neuroscience.

[32]  Roger A. Barker,et al.  Perseveration and Choice in Parkinson's Disease: The Impact of Progressive Frontostriatal Dysfunction on Action Decisions , 2012, Cerebral cortex.

[33]  D H Brainard,et al.  The Psychophysics Toolbox. , 1997, Spatial vision.

[34]  M Schulzer,et al.  Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease , 2001, Science.

[35]  D. Wolpert,et al.  Abnormalities in the awareness and control of action. , 2000, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[36]  Marjan Jahanshahi,et al.  What contributes to quality of life in patients with Parkinson's disease? , 2000, Journal of neurology, neurosurgery, and psychiatry.

[37]  E. Nestler,et al.  Molecular basis of long-term plasticity underlying addiction , 2001, Nature Reviews Neuroscience.

[38]  C. Clarke,et al.  Systematic review of levodopa dose equivalency reporting in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[39]  Monica Gori,et al.  Parkinson's disease accelerates age-related decline in haptic perception by altering somatosensory integration. , 2012, Brain : a journal of neurology.

[40]  M. Merello,et al.  Addenbrooke’s Cognitive Examination validation in Parkinson’s disease , 2009, European journal of neurology.

[41]  T. Robbins,et al.  Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. , 2007, Brain : a journal of neurology.

[42]  Luis F. Schettino,et al.  Hand preshaping in Parkinson’s disease: effects of visual feedback and medication state , 2005, Experimental Brain Research.

[43]  David M. Ludlum An Uneven Pattern , 1984 .

[44]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[45]  Emily Balcetis,et al.  See what you want to see: motivational influences on visual perception. , 2006, Journal of personality and social psychology.

[46]  R. Carpenter,et al.  Saccadic latency in Parkinson's disease correlates with executive function and brain atrophy, but not motor severity , 2011, Neurobiology of Disease.

[47]  Angie A. Kehagia,et al.  Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease , 2010, The Lancet Neurology.

[48]  Stanley Fahn,et al.  Levodopa: 50 years of a revolutionary drug for Parkinson disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[49]  S. Fahn Unified Parkinson's Disease Rating Scale , 1987 .

[50]  J. Nutt,et al.  Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease , 1995, Neurology.

[51]  M. B. Bender,et al.  Oculomotor function in patients with Parkinson's disease. , 1972, Journal of the neurological sciences.

[52]  J. Rowe,et al.  Beyond the “urge to move”: objective measures for the study of agency in the post-Libet era , 2014, Front. Hum. Neurosci..

[53]  G. Schwarz Estimating the Dimension of a Model , 1978 .

[54]  Hartwig R. Siebner,et al.  Cue integration and the perception of action in intentional binding , 2013, Experimental Brain Research.

[55]  R. Dolan,et al.  Dopamine Enhances Expectation of Pleasure in Humans , 2009, Current Biology.

[56]  Zoubin Ghahramani,et al.  Computational principles of movement neuroscience , 2000, Nature Neuroscience.

[57]  D. Wolpert,et al.  Seeing what you want to see: priors for one's own actions represent exaggerated expectations of success , 2014, Front. Behav. Neurosci..

[58]  H. Vankova Mini Mental State , 2010 .

[59]  Mark Hallett,et al.  Impulsive choice and response in dopamine agonist-related impulse control behaviors , 2009, Psychopharmacology.

[60]  A. Grace,et al.  Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[61]  J. Dichgans,et al.  Visual control of arm movement in Parkinson's disease , 1994, Movement disorders : official journal of the Movement Disorder Society.

[62]  Michael I. Jordan,et al.  Computational models of sensorimotor integration , 1997 .

[63]  T. Robbins,et al.  The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. , 2012, Brain : a journal of neurology.

[64]  B. Amblard,et al.  Increased Visual Dependence in Parkinson's Disease , 2002, Perceptual and motor skills.

[65]  William E. S. McNeill Seeing what you want , 2015, Consciousness and Cognition.

[66]  Brent L. Hughes,et al.  Neural systems of social comparison and the “above-average” effect , 2010, NeuroImage.

[67]  Jean-Philippe Azulay,et al.  Influence of visual cues on gait in Parkinson's disease: Contribution to attention or sensory dependence? , 2006, Journal of the Neurological Sciences.

[68]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[69]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[70]  Patrick Haggard,et al.  Dopaminergic medication boosts action–effect binding in Parkinson's disease , 2010, Neuropsychologia.

[71]  B. Dubois,et al.  Motivation, reward, and Parkinson’s disease: influence of dopatherapy , 2002, Neuropsychologia.

[72]  C. Marsden,et al.  Fronto-striatal cognitive deficits at different stages of Parkinson's disease. , 1992, Brain : a journal of neurology.